Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial-Efficacy and Biomarker Discovery.
Kathy S AlbainChristina YauEmanuel F PetricoinDenise M WolfJulie E LangAmy Jo ChienTufia C HaddadAndres Forero-TorresAnne M WallaceHenry G KaplanLajos PusztaiDavid M EuhusRita NandaAnthony D EliasAmy S ClarkConstantine GodellasJudy C BougheyClaudine IsaacsDebasish TripathyJanice LuRachel L YungRosa I GallagherJulia D WulfkuhleLamorna Brown SwigartGregor KringsYunn Yi ChenDavid A PotterErica M Stringer-ReasorSarah L BlairSmita M AsareAmy WilsonGillian L HirstRuby SinghraoMeredith BuxtonJulia L ClennellAshish SanilScott BerryAdam L AsareJeffrey B MatthewsAngela M DeMicheleNola M HyltonMichelle E MeliskoJane PerlmutterHope S RugoWilliam Fraser SymmansLaura van 't VeerDouglas YeeDonald A BerryLaura J EssermanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The angiopoietin (Ang)/Tie2 axis inhibitor trebananib combined with standard neoadjuvant therapy increased estimated pCR rates across HR-negative and MP2 subtypes, with probabilities of superiority >90%. Further study of Ang/Tie2 receptor axis inhibitors in validated, biomarker-predicted sensitive subtypes is warranted.
Keyphrases
- locally advanced
- rectal cancer
- phase iii
- angiotensin ii
- lymph node
- phase ii
- open label
- clinical trial
- small molecule
- double blind
- squamous cell carcinoma
- radiation therapy
- placebo controlled
- high throughput
- randomized controlled trial
- stem cells
- mesenchymal stem cells
- bone marrow
- young adults
- smoking cessation
- childhood cancer